Justin Kim
Stock Analyst at Oppenheimer
(1.35)
# 3,538
Out of 5,182 analysts
39
Total ratings
45.16%
Success rate
-3.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Outperform | $16 → $15 | $5.81 | +158.18% | 3 | Mar 20, 2026 | |
| PHVS Pharvaris | Maintains: Outperform | $44 → $50 | $28.56 | +75.07% | 5 | Dec 4, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $65 → $40 | $40.90 | -2.20% | 6 | Nov 6, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $107 → $106 | $66.71 | +58.90% | 5 | May 9, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Outperform | $85 → $87 | $31.45 | +176.63% | 5 | Feb 29, 2024 | |
| VERA Vera Therapeutics | Initiates: Outperform | $26 | $42.30 | -38.53% | 1 | Jan 25, 2024 | |
| ALDX Aldeyra Therapeutics | Downgrades: Perform | n/a | $1.80 | - | 2 | Oct 17, 2023 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Perform | n/a | $16.05 | - | 6 | Nov 4, 2022 | |
| BCRX BioCryst Pharmaceuticals | Downgrades: Perform | n/a | $9.50 | - | 5 | Aug 8, 2022 | |
| IONS Ionis Pharmaceuticals | Assumes: Outperform | $59 | $75.71 | -22.07% | 1 | Jul 18, 2022 |
Zura Bio
Mar 20, 2026
Maintains: Outperform
Price Target: $16 → $15
Current: $5.81
Upside: +158.18%
Pharvaris
Dec 4, 2025
Maintains: Outperform
Price Target: $44 → $50
Current: $28.56
Upside: +75.07%
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Outperform
Price Target: $65 → $40
Current: $40.90
Upside: -2.20%
Cytokinetics
May 9, 2024
Maintains: Outperform
Price Target: $107 → $106
Current: $66.71
Upside: +58.90%
Immunocore Holdings
Feb 29, 2024
Reiterates: Outperform
Price Target: $85 → $87
Current: $31.45
Upside: +176.63%
Vera Therapeutics
Jan 25, 2024
Initiates: Outperform
Price Target: $26
Current: $42.30
Upside: -38.53%
Aldeyra Therapeutics
Oct 17, 2023
Downgrades: Perform
Price Target: n/a
Current: $1.80
Upside: -
Aurinia Pharmaceuticals
Nov 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $16.05
Upside: -
BioCryst Pharmaceuticals
Aug 8, 2022
Downgrades: Perform
Price Target: n/a
Current: $9.50
Upside: -
Ionis Pharmaceuticals
Jul 18, 2022
Assumes: Outperform
Price Target: $59
Current: $75.71
Upside: -22.07%